PROCEPT BioRobotics Corporation Overview
Pro stress-test →PROCEPT BioRobotics is a surgical robotics company focused on advancing patient care by developing transformative solutions in urology. The company has demonstrated strong clinical impact with more than 125,000 patients treated to date, positioning itself as a critical player in the robotic urology treatment space.
Strategic Profile
Pro stress-test →The company's Aquablation therapy is designed to deliver effective, safe, and durable outcomes for males suffering from lower urinary tract symptoms due to benign prostatic hyperplasia (BPH) independent of prostate size and shape or surgeon experience. With current Aquablation market penetration at approximately 10% of the treated market where roughly 400,000 patients per year undergo prostate procedures, PROCEPT has substantial headroom for growth from millions of men on drug therapy.
Competitive Landscape
Pro stress-test →PROCEPT operates in the robotic urology market competing against established surgical robotics players and traditional treatment approaches. The company differentiates through its proprietary Aquablation technology using high-velocity water jet precision, AI-powered automation, and clinical evidence demonstrating superior outcomes. With only ~10% market penetration in its addressable BPH market and significant reimbursement advantages, PROCEPT has substantial competitive positioning advantage as it scales.
Industry Context
PROCEPT BioRobotics Corporation operates in Medical Devices - Robotic Surgical Systems / Urology.
Key facts
Headquarters: San Jose, California · Revenue: $390-$410M (2026 guidance)